Eli Lilly and Company (NYSE:LLY) Holdings Lifted by Acropolis Investment Management LLC

Acropolis Investment Management LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,666 shares of the company’s stock after buying an additional 47 shares during the period. Acropolis Investment Management LLC’s holdings in Eli Lilly and Company were worth $1,476,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. L.M. Kohn & Company grew its stake in shares of Eli Lilly and Company by 13.4% in the third quarter. L.M. Kohn & Company now owns 2,725 shares of the company’s stock worth $2,414,000 after purchasing an additional 323 shares in the last quarter. Kolinsky Wealth Management LLC lifted its holdings in Eli Lilly and Company by 20.4% in the third quarter. Kolinsky Wealth Management LLC now owns 425 shares of the company’s stock worth $377,000 after purchasing an additional 72 shares during the period. Eventide Asset Management LLC grew its position in Eli Lilly and Company by 249.2% in the 3rd quarter. Eventide Asset Management LLC now owns 4,128 shares of the company’s stock valued at $3,657,000 after buying an additional 2,946 shares in the last quarter. CWS Financial Advisors LLC increased its stake in Eli Lilly and Company by 7.3% during the 3rd quarter. CWS Financial Advisors LLC now owns 1,200 shares of the company’s stock valued at $1,063,000 after buying an additional 82 shares during the period. Finally, Carl P. Sherr & Co. LLC raised its position in shares of Eli Lilly and Company by 0.4% during the 3rd quarter. Carl P. Sherr & Co. LLC now owns 5,526 shares of the company’s stock worth $4,896,000 after buying an additional 24 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

NYSE LLY opened at $795.35 on Friday. Eli Lilly and Company has a 52-week low of $561.65 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The firm has a market capitalization of $755.04 billion, a price-to-earnings ratio of 85.98, a price-to-earnings-growth ratio of 2.99 and a beta of 0.43. The company has a 50 day simple moving average of $851.90 and a 200-day simple moving average of $869.52.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company’s revenue was up 20.4% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share. Equities research analysts predict that Eli Lilly and Company will post 13.2 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. BMO Capital Markets boosted their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Berenberg Bank raised their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Finally, Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.